Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID-19
Complement, a critical defence against pathogens, has been implicated as a driver of pathology in COVID-19. Complement activation products are detected in plasma and tissues and complement blockade considered for therapy. To delineate roles of complement in immunopathogenesis, we undertook the large...
Main Authors: | Siggins, M, Davies, K, Fellows, R, Thwaites, R, Baillie, K, Semple, M, Openshaw, P, Zelek, W, Harris, CL, Morgan, BP, Dunning, W |
---|---|
Other Authors: | The ISARIC4C Investigators |
Format: | Journal article |
Language: | English |
Published: |
Wiley
2022
|
Similar Items
-
Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species
by: Wioleta M. Zelek, et al.
Published: (2020-12-01) -
Terminal complement pathway activation drives synaptic loss in Alzheimer’s disease models
by: Sarah M. Carpanini, et al.
Published: (2022-07-01) -
Dysregulation of complement system in HELLP syndrome
by: Shi Chen, et al.
Published: (2021-10-01) -
Measuring Total Classical Pathway and Activities of Individual Components of the Mouse Complement Pathway
by: Wioleta Zelek
Published: (2021-10-01) -
Chronic complement dysregulation drives neuroinflammation after traumatic brain injury: a transcriptomic study
by: Amer Toutonji, et al.
Published: (2021-07-01)